At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of chronic lymphocytic leukemia (CLL) by flow cytometry
- ✓Relapsed or refractory disease
- ✓Measurable disease: absolute lymphocyte count ≥5,000/mm³ or measurable lymphadenopathy/organomegaly
- ✓At least 1 prior therapy for CLL
- ✕Prior lenalidomide (CC-5013) therapy
- ✕Known hypersensitivity to thalidomide
- ✕Erythema nodosum with desquamating rash after prior thalidomide or similar drug
- ✕Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CC-5013 Alone or in Combination With Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
In Brief
A Phase 2 clinical trial evaluating rituximab and lenalidomide for Leukemia. Completed, enrolled 45 participants across 1 site.
Detailed Summary
RATIONALE: Biological therapies such as lenalidomide use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining lenalidomide with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the how well giving lenalidomide with or without rituximab works in treating patients with relapsed or refractory chronic lymphocytic leukemia.
Study Details
Timeline
Interventions
IV
Oral